评估IgA肾病患者的进展风险
该综述总结IgA肾病患者肾功能下降速率高度可变,预测进展至肾衰竭困难;现有标志物主要依赖诊断性肾活检的组织学特征和标准临床数据,缺乏反映疗效的无创标志物;补体激活等新型预后标志物正在研究中。
要点
- IgA肾病肾功能下降速率高度可变,预测进展至肾衰竭及速度困难。
- 现有标志物依赖肾活检组织学特征和标准临床数据指导治疗选择。
- 补体激活等新型预后和预测标志物正在临床研究中。
核心结论
- IgA肾病患者肾功能下降速率高度可变,预测进展至肾衰竭及速度困难。
- 现有标志物虽有用但使临床医生严重依赖诊断性肾活检的组织学特征和标准临床数据来指导治疗选择。
- 很少有非侵入性标志物能反映随时间推移的治疗疗效。
- 新型预后和预测标志物正在临床研究中,补体激活标志物取得相当大的进展。
研究设计与样本
- 综述总结了临床医生工具包中已知的人口统计学、临床和组织病理学预后标志物,包括国际IgA肾病预测工具。
- 简要回顾了儿童和青少年IgA肾病患者中这些主题的已知信息。
- 描述了预测和预后标志物在IgA肾病中走向临床应用的路径。
主要发现
- IgA肾病患者肾功能下降速率高度可变。
- 预测哪些患者将进展至肾衰竭以及进展速度困难。
- 多种新型疗法可能在短期内获批,但临床医生缺乏工具在正确时间识别最可能从特定治疗中获益的患者。
- 迫切需要非侵入性和经过验证的标志物来选择高危患者和进行纵向监测。
- 补体激活标志物的研究取得相当大的进展。
临床怎么用
- 临床医生目前严重依赖诊断性肾活检的组织学特征和标准临床数据来指导治疗选择。
- 使用 robust、临床实用的标志物为患者护理提供信息,以改善IgA肾病预后。
局限性
- 目前使用的标志物虽有用,但使临床医生严重依赖组织学特征和标准临床数据。
- 很少有非侵入性标志物反映随时间推移的治疗疗效。
- 生物标志物研究仍存在空白,需要解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The highly variable rate of decline in kidney function in patients with immunoglobulin A nephropathy (IgAN) provides a major clinical challenge. Predicting which patients will progress to kidney failure, and how quickly, is difficult. Multiple novel therapies are likely to be approved in the short-term, but clinicians lack the tools to identify patients most likely to benefit from specific treatments at the right time. Noninvasive and validated markers for selecting at-risk patients and longitudinal monitoring are urgently needed. This review summarizes what is known about demographic, clinical, and histopathologic prognostic markers in the clinician's toolkit, including the International IgAN Prediction Tool. We also briefly review what is known on these topics in children and adolescents with IgAN. Although helpful, currently used markers leave clinicians heavily reliant on histologic features from the diagnostic kidney biopsy and standard clinical data to guide treatment choice, and very few noninvasive markers reflect treatment efficacy over time. Novel prognostic and predictive markers are under clinical investigation, with considerable progress being made in markers of complement activation. Other areas of research are the interplay between gut microbiota and galactose-deficient IgA1 expression; microRNAs; imaging; artificial intelligence; and markers of fibrosis. Given the rate of therapeutic advancement, the remaining gaps in biomarker research need to be addressed. We finish by describing our route to clinical utility of predictive and prognostic markers in IgAN. This route will provide us with the chance to improve IgAN prognosis by using robust, clinically practical markers to inform patient care.
引用
- Cattran DC, Floege J, Coppo R, et al. Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy. Kidney Int Rep. 2023. PMID: 38106572. doi:10.1016/j.ekir.2023.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。